Further characterization of ΔaroA ΔvirG shigella flexneri 2a strain CVD 1203 as a mucosal shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic escherichia coli

Infection and Immunity

Volumn 64, Issue 1, 1996, Pages 23-27

  Noriega, Fernando R ^a   Losonsky, Genevieve ^a   Wang, Jin Yuan ^a   Formal, Samuel B ^a   Levine, Myron M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI ENTEROTOXIN; ESCHERICHIA COLI VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; SHIGELLA VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ENTEROBACTER INFECTION; ESCHERICHIA COLI; GUINEA PIG; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; INFECTION PREVENTION; INTRANASAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SHIGELLA FLEXNERI; VACCINE PRODUCTION;

3-PHOSPHOSHIKIMATE 1-CARBOXYVINYLTRANSFERASE; ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; DNA-BINDING PROTEINS; DRUG ADMINISTRATION ROUTES; DYSENTERY, BACILLARY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FIMBRIAE PROTEINS; GASTRIC MUCOSA; GUINEA PIGS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGIC TESTS; MICE; MOUTH MUCOSA; NASAL MUCOSA; SEQUENCE DELETION; SHIGELLA FLEXNERI; TRANSCRIPTION FACTORS; TRANSFERASES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 0029671022     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.64.1.23-27.1996     Document Type: Article

References (18)

1. Couch, R. B. 1943 Advances in influenza virus vaccine research. Ann N Y. Acad. Sci. 685:803-812.
2. Du Pont, H. L., R. B. Hornick, A. T. Dawkins, M. J. Snyder, and S. B. Formal. 1969. The response of man to virulent Shigella flexneri 2a. J. Infect. Dis. 119:296-299.
3. Formal, S. B., G. J. Dammin, E. H. LaBrec. and H. Schneider. 1958. Experimental Shigella infections characteristics of a fatal infection produced in guinea pigs J Bacteriol. 75:604-610.
4. Giron, J. A., J. G. Xu, C. R. Gonzalez, D. Hone, J. B. Kaper, and M. M. Levine. 1995. Simultaneous expression of CFA/I and CS3 colonization factor antigens of enterotoxigenic Escherichia coli by aroC,aroD Salmonella typhi vaccine strain CVD 908. Vaccine 13:939-946.
5. Hall, R. H., D. R. Maneval, Jr., J. H. Collins, J. L. Theibert, and M. M. Levine. 1989. Purification and analysis of colonization factor antigen 1, coli surface antigen 1, and coli surface antigen 3 fimbriae from enterotoxigenic Escherichia coli. J Bacteriol 171:6372-6374.
6. Kotloff, K. L., G. A. Losonsky, J. Nataro, S. S. Wasserman, T. L. Hale, D. N. Taylor, J. W. Newland, J. C. Sadoff, S. B. Formal, and M. M. Levine. 1995 Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine 13:495-502.
7. Langermann, S., S. Palaszynski, A. Sadziene, C. K. Stover, and S. Koening. 1994. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borielia burgdorferi. Nature (London) 372:552-555.
8. Levine, M. M. 1987. Escherichia coli that cause diarrhea: enterotoxigenic. enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J. Infect. Dis. 155:377-389
9. Levine, M. M. 1990. Vaccines against enterotoxigenic Escherichia coli infections. Vaccines based predominantly in antibacterial immunity, p. 649-660. In G. C. Woodrow and M M. Levine (ed.). New generation vaccines: the molecular approach. Marcel Dekker, Inc., New York.
10. Levine, M. M., E. J. Bergquist, D. R. Nalin, D. H. Waterman, R. B. Hornick, C. R. Young, S. Sotman, and B. Rowe. 1978 Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxms and are not invasive. Lancet 1:1119-1122.
11. Levine, M. M., J. Giron, and F. Noriega. 1994 Fimbrial vaccines, p. 255-276. In P. Klemm (ed.), Fimbriae: adhesion, biogenics, genetics and vaccines. CRC Press. Inc, Boca Raton, Fla.
12. Levine, M. M., D. R. Nalin, D. L. Hoover, E. J. Bergquist, R. B. Hornick, and C. R. Young. 1979. Immunity to enterotoxigenic Escherichia coli Infect Immun. 23:729-736.
13. Mestecky, J., and J. R. McGhee. 1992. Prospects for human mucoSal vaccines, p. 13-23. In J. E. Ciardi (ed.). Genetically engineered vaccines Plenum Press, New York.
14. Natuk, R. J., A. R. Davis, P. K. Chanda, M. D. Lubeck, M. Chengalvala, S. C. Murthy, and M. S. Wade. 1994. Adenovirus vectored vaccines. Dev. Biol. Stand. 82:71-77.
15. Noriega, F. R., J. Y. Wang, G. Losonsky, D. R. Maneval, D. M. Hone, and M. M. Levine. 1994 Construction and characterization of attenuated ΔaroA ΔvirG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine Infect. Immun 62:5168-5172.
16. Orr, N., G. Robin, D. Cohen, R. Arnon, and G. H. Lowell. 1993. Immuno genicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei. Infect. Immun 61:2390-2395.
17. Sereny, B. 1957. Experimental keratoconjunctivitis shigellosa. Acta Micro-biol Acad. Sci Hung. 4:367-376
18. Westphal, O., and K. Jann. 1965 Bacterial lipopolysaccharides: extraction with phenol-water and further application of procedures. Methods Carbohydr. Chem. 5:83-91.